Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra

Rheumatology (Oxford). 2021 Nov 3;60(11):e375-e377. doi: 10.1093/rheumatology/keab383.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / classification
  • Drug Resistance / drug effects
  • Drug Resistance / immunology
  • Drug Therapy, Combination / methods
  • Gout* / blood
  • Gout* / drug therapy
  • Gout* / physiopathology
  • Humans
  • Injections, Subcutaneous
  • Interleukin 1 Receptor Antagonist Protein* / administration & dosage
  • Interleukin 1 Receptor Antagonist Protein* / adverse effects
  • Male
  • Middle Aged
  • Patient Acuity
  • Receptors, Interleukin-1 / antagonists & inhibitors
  • Receptors, Interleukin-6 / antagonists & inhibitors*
  • Severity of Illness Index
  • Treatment Outcome
  • Uric Acid / blood

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1
  • Receptors, Interleukin-6
  • Uric Acid
  • tocilizumab